Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The interval for cervical cancer screening could be safely extended beyond 5 years for women aged 40 and older who are negative for human papillomavirus (HPV), researchers conclude in The BMJ.
In a population-based Dutch study, women aged 29–61 were randomized to screening with both HPV testing and cytology (the intervention group) or cytology with blinded HPV testing (controls). The current analysis included over 40,000 participants who had an initial negative HPV or cytology result and thus were referred for routine screening every 5 years.
During 14 years' follow-up, the incidences of cancer and cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among HPV-negative women in the intervention group after three screens (i.e., 14 years after baseline) were low — and were similar to the incidences in the control group after two screens (9 years after baseline). Further, the incidence of CIN3+ was significantly lower among HPV-negative women aged 40 and older than among younger women.
Dr. Anna Wald, an associate editor of NEJM Journal Watch Women's Health, comments: "These findings suggest that as we move toward cervical cancer screening that is based on HPV and not cytology, the interval between screening can be lengthened, although the length of a safe interval for HPV-negative women over the age of 40 is not yet clear."
Comment
LINK(S):
The BMJ article (Free)
Background: NEJM Journal Watch Women's Health coverage of several 2015 articles suggesting it may be time to shorten the cervical screening interval (Your NEJM Journal Watch registration required)